MF
SNDX icon

Magnetar Financial’s Syndax Pharmaceuticals SNDX Stock Holding History

Magnetar Financial’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$252K Buy
+10,791
New +$234K ﹤0.01% 818
2025
Q2 		– Sell
-10,717
Closed -$132K – 1122
2025
Q1 		$132K Buy
+10,717
New +$151K ﹤0.01% 694

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Magnetar Financial's SNDX Position: Q1 2026 in Review

Magnetar Financial opened a new position in Syndax Pharmaceuticals (SNDX) in Q1 2026: 10,791 shares worth $252K. The stake represents ﹤0.01% of the portfolio and ranks #818 among its holdings. This is a return to the name: Magnetar Financial previously reported a position in SNDX as recently as Q1 2025.

Magnetar Financial first reported a position in SNDX in Q1 2025 and has held it in 2 quarters since. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • Magnetar Financial held 10,791 shares of Syndax Pharmaceuticals worth $252K as of Q1 2026.
  • Syndax Pharmaceuticals was a new Magnetar Financial position in Q1 2026.
  • Syndax Pharmaceuticals made up ﹤0.01% of Magnetar Financial's portfolio in Q1 2026, its #818 holding.
  • Magnetar Financial first reported a position in Syndax Pharmaceuticals in Q1 2025 and has held it in 2 quarters since.
  • 246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Magnetar Financial's 13F filing for Q1 2026, filed 13 May 2026.